Predictive Biomarkers Market Size

Predictive Biomarkers Market size was over USD 20.3 Billion in 2023 and is likely to exceed USD 29.5 Billion by the end of 2036, growing at over 18.9% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of predictive biomarkers is evaluated at USD 21 Billion. The reason behind the growth is the rising prevalence of chronic diseases, such as cancer, and diabetes across the globe. Predictive biomarkers help in predicting disease progression and assessing the risk of developing certain diseases. For instance, elevated levels of below 4.0 ng/mL prostate-specific antigen in the blood can be a predictive biomarker for prostate cancer and are the most used biomarker in the management of early prostate cancer.  According to the data from the World Health Organization (WHO), over 422 million people around the world suffer from diabetes, and it causes about 1.6 million deaths every year, whereas cancer caused over 10 million deaths in 2020.

The growing geriatric population is believed to fuel the market growth since older populations are more prone to diseases such as cardiovascular disease, and also cancer. Hence, the demand for predictive biomarkers is expected to increase to diagnose age-related conditions. According to World Health Organization, the number of people 60 and older in the world is expected to double (2.1 billion) by 2050.